New developments in imaging, digital biomarkers and gene therapy are significantly changing the diagnosis and treatment of ataxia. Experts emphasize the clinically central distinction between sensitive and cerebellar ataxia, the importance of structured diagnostics and the rise of digital procedures and precise biomarkers that could enable preventive therapies in the future.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Analysis of SNVCS data from the period 2005-2022
TBE vaccination for children and adolescents in Switzerland
- Tuberculosis
Detecting diabetes in TB patients early and efficiently
- Trichophyton indotineae
Terbinafine-resistant dermatophytoses are on the rise in Central Europe
- Peristomal skin health
Focus on preventive care options
- Disease-modifying therapies for ATTR-CM
TTR stabilizers, gene silencing and gene scissors: where do we stand?
- Proteins in wound healing
Do special amino acids lead to success?
- HER2+ early breast cancer
DESTINY-Breast11 – neoadjuvant T-DXd without anthracyclines
- Lavender aromatherapy